Expression of Tuberculosis in the Lung
|Study Design:||Observational Model: Case Control
Time Perspective: Cross-Sectional
|Official Title:||Expression of Tuberculosis in the Lung|
- Pulmonary immune responses associated with resistance and susceptibility to Mycobacterium tuberculosis infection (measured at baseline) [ Time Frame: one week ]
Biospecimen Retention: Samples With DNA
Cell culture supernatants and cell lysates from bronchoalveolar cells, as well as peripheral blood mononuclear cells.
Bronchoalveolar lavage fluid
|Study Start Date:||September 2000|
|Study Completion Date:||June 2008|
|Primary Completion Date:||June 2008 (Final data collection date for primary outcome measure)|
M. tuberculosis infects a third of the world's population, and TB is the leading cause of morbidity and mortality due to a single infectious agent. However, only 5% to 10% of M. tuberculosis-infected subjects without an underlying immunodeficiency develop disease during their lifetimes. Therefore protective immunity is induced in the majority of subjects. Understanding correlates of protection against M. tuberculosis in humans is needed to better direct efforts in the development of antituberculosis vaccines.
Patients are treated according to good clinical practice; however, no study medications are given as part of the research study. This study involves a one-time bronchoalveolar lavage and venipuncture to obtain immune cells for laboratory studies of immune responses.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00201253
|United States, New Jersey|
|UMDNJ-New Jersey Medical School|
|Newark, New Jersey, United States, 07103|
|Instituto Nacional de Enfermedades Respiratorias (INER)|
|Mexico City, Mexico|
|Principal Investigator:||Jerrold Ellner||UMDNJ-New Jersey Medical School|